Meeting
2016 ASCO Annual Meeting
Efficacy and hematologic toxicity of carboplatin and talazoparib combination therapy in BRCA mutated patients.
Authors
Mallika Sachdev Dhawan
University of California, San Francisco, San Francisco, CA
Mallika Sachdev Dhawan , Rahul Raj Aggarwal , Imke Bartelink , Jim Leng , Scott Thomas , Nela Pawlowska , Laurie Stevenson , Amy Jo Chien , Robin Kate Kelley , Julia Clennell , Pamela N. Munster
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Other Novel Agents
Clinical Trial Registration Number
NCT02358200
Citation
J Clin Oncol 34, 2016 (suppl; abstr 2557)
DOI
10.1200/JCO.2016.34.15_suppl.2557
Abstract #
2557
Poster Bd #
257
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Differential efficacy of PARP inhibitors in metastatic castration-resistant prostate cancer with DNA repair defects: A systematic review and meta-analysis.
First Author: Syed Arsalan Ahmed Naqvi
Poster
2020 Genitourinary Cancers Symposium
A pilot study of docetaxel and carboplatin for treatment of patients with mCRPC containing biallelic inactivation of genes in the BRCA1/2 pathway.
First Author: Heather H. Cheng
Poster
2017 ASCO Annual Meeting
A phase I study of carboplatin and talazoparib in patients with and without DNA repair mutations.
First Author: Mallika Sachdev Dhawan
Poster
2021 ASCO Annual Meeting
Phase 1b/2 SEASTAR trial: Safety, pharmacokinetics, and preliminary efficacy of the poly(ADP)-ribose polymerase (PARP) inhibitor rucaparib and angiogenesis inhibitor lucitanib in patients with advanced solid tumors.
First Author: Ecaterina Elena Dumbrava